<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00788307</url>
  </required_header>
  <id_info>
    <org_study_id>MC0252</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC0252</secondary_id>
    <secondary_id>06-009392</secondary_id>
    <secondary_id>NCI-2009-01195</secondary_id>
    <nct_id>NCT00788307</nct_id>
  </id_info>
  <brief_title>Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy</brief_title>
  <official_title>Phase I Trial of In Situ Gene Therapy for Locally Recurrent Prostate Cancer Following Radiation Therapy Failure Using Sodium/Iodide Symporter and Radioiodine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radioactive drugs, such as radioactive iodine, may carry radiation directly to&#xD;
      tumor cells and not harm normal cells. Placing a gene called Ad5CMV-NIS in prostate cancer&#xD;
      cells may help the prostate cells take in more radioactive iodine and thus kill the cancer&#xD;
      cells. Drugs, such as liothyronine sodium, may protect the thyroid from the side effects of&#xD;
      radioactive iodine.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of gene therapy given&#xD;
      together with radioactive iodine in treating patients with locally recurrent prostate cancer&#xD;
      that did not respond to external-beam radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the safety and tolerance of Ad5CMV-NIS administered intraprostatically&#xD;
           followed by radioiodine treatment in patients with locally recurrent adenocarcinoma of&#xD;
           the prostate following external beam radiotherapy.&#xD;
&#xD;
        -  To determine the maximum tolerated dose of Ad5CMV-NIS in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate the PSA response rates, duration, and time to PSA progression in these&#xD;
           patients.&#xD;
&#xD;
        -  To evaluate the immune response to Ad5CMV-NIS.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of Ad5CMV-NIS.&#xD;
&#xD;
      Patients receive intraprostate Ad5CMV-NIS, via transperineal injection under anesthesia, on&#xD;
      day 1. They receive dosimetry oral iodine I 123 on day 4 and undergo image studies&#xD;
      periodically for the next 24 hours for measurement of radioiodine uptake. Patients receive&#xD;
      therapeutic oral iodine I 131 on day 5.&#xD;
&#xD;
      All patients with intact thyroid glands (i.e., not previously surgically removed or ablated)&#xD;
      receive TSH suppressive doses of oral liothyronine sodium 3 times daily for 10 days prior and&#xD;
      for 15 days post administration of iodine I 123.&#xD;
&#xD;
      Blood samples are collected periodically for measurement of PSA, fT4, and TSH; and peripheral&#xD;
      blood cells are monitored for evidence of virus DNA via quantitative&#xD;
      reverse-transcriptase-PCR.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months for 1 year, every 4&#xD;
      months for 1 year, and then every 6 months for 8 years. A transrectal tumor biopsy is to be&#xD;
      performed at 3 months and 1 year post-treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    closed early due to poor accrual&#xD;
  </why_stopped>
  <start_date type="Actual">November 3, 2008</start_date>
  <completion_date type="Actual">February 7, 2018</completion_date>
  <primary_completion_date type="Actual">February 7, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of toxicity incidents by NCI CTCAE v3.0 criteria</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to PSA progression</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of PSA response</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of PSA control</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad5-CMV-NIS</intervention_name>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liothyronine sodium</intervention_name>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iodine I 131</intervention_name>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed recurrent adenocarcinoma of the prostate within the past year&#xD;
&#xD;
               -  No transitional cell, small cell, or squamous cell carcinoma of the prostate&#xD;
&#xD;
               -  Local recurrence&#xD;
&#xD;
          -  Disease recurred ≥ 18 months after completion of prior external beam radiotherapy&#xD;
             (EBRT) for stage T1-T2b, N0/X, M0 disease&#xD;
&#xD;
               -  Biochemical failure as defined by the Phoenix definition (rise in PSA by 2 ng/mL&#xD;
                  or more above the nadir PSA)&#xD;
&#xD;
                    -  PSA ≥ 0.3 ng/mL to &lt; 20 ng/mL measured within the past 30 days&#xD;
&#xD;
               -  Pre-EBRT PSA &lt; 50 ng/mL&#xD;
&#xD;
               -  Prior locally recurrent hormone-refractory disease allowed&#xD;
&#xD;
          -  American Urologic Association Obstructive Symptom Index Score ≤ 24&#xD;
&#xD;
          -  No known standard therapy that is potentially curative or definitely capable of&#xD;
             extending life expectancy&#xD;
&#xD;
          -  No evidence of or history of metastatic adenocarcinoma of the prostate&#xD;
&#xD;
               -  Negative radiographic metastatic work-up including whole-body radionuclide bone&#xD;
                  scan, CT and/or MR scan of the pelvis and abdomen, and chest x-ray&#xD;
&#xD;
                    -  Patients with suspicious areas on conventional imaging studies are eligible&#xD;
                       provided they are biopsy negative&#xD;
&#xD;
               -  No known CNS metastases&#xD;
&#xD;
          -  No prostate size &gt; 140 cc&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  ANC ≥ 1,500/μL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/μL&#xD;
&#xD;
          -  Hemoglobin ≥ 8.5 g/dL&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  INR ≤ 1.4 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Thyroid-stimulating hormone 0.3-5.0 uIU/mL and free thyroxine 0.8-1.87 ng/dL&#xD;
&#xD;
          -  Willing to provide biologic specimens and participate in imaging studies as required&#xD;
&#xD;
          -  Willing to maintain a low-iodine diet for 12 days&#xD;
&#xD;
               -  Starting 7 days prior to study virus injection continuing until after the iodine&#xD;
                  I 131 radioiodine therapy on day 5&#xD;
&#xD;
          -  No more than 1 of the following renal/genitourinary toxicities:&#xD;
&#xD;
               -  Bladder spasms&#xD;
&#xD;
               -  Dysuria (painful urination)&#xD;
&#xD;
               -  Genitourinary fistula&#xD;
&#xD;
               -  Hemoglobinuria&#xD;
&#xD;
               -  Incontinence&#xD;
&#xD;
               -  Operative injury to bladder and/or ureter&#xD;
&#xD;
               -  Proteinuria&#xD;
&#xD;
               -  Renal failure&#xD;
&#xD;
               -  Uretal obstruction&#xD;
&#xD;
               -  Urinary frequency/urgency&#xD;
&#xD;
               -  Urinary retention&#xD;
&#xD;
               -  Urine color change (not related to other dietary or physiologic cause [e.g.,&#xD;
                  bilirubin, concentrated urine, or hematuria])&#xD;
&#xD;
               -  Other renal/genitourinary toxicities&#xD;
&#xD;
          -  No urinary tract infection within 72 hours prior to registration&#xD;
&#xD;
          -  No pubic arch interference study demonstrating unacceptable prostate access by the&#xD;
             transperineal approach&#xD;
&#xD;
          -  No absence of rectum or other anatomic features that would preclude transperineal&#xD;
             needle insertion into the prostate&#xD;
&#xD;
          -  No coagulopathy that contraindicates transperineal and intraprostatic needle insertion&#xD;
&#xD;
          -  No other cancer within the past 2 years, except for squamous cell and basal cell skin&#xD;
             cancers&#xD;
&#xD;
          -  No uncontrolled infection or fever &gt; 100°F&#xD;
&#xD;
          -  No known cardiac disease&#xD;
&#xD;
          -  No seizure disorder&#xD;
&#xD;
          -  No documented history of HIV positivity or other acquired immunodeficiency disorder or&#xD;
             congenital immunodeficiency disorder&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from acute, reversible effects of prior chemotherapy&#xD;
&#xD;
          -  Androgen-deprivation therapy (if applicable) initiated more than 3 months prior to&#xD;
             registration&#xD;
&#xD;
               -  Patients who have undergone bilateral orchiectomy are eligible if they meet all&#xD;
                  other criteria&#xD;
&#xD;
          -  At least 6 weeks since prior bicalutamide, nilutamide, or oral or intravenous&#xD;
             iodinated contrast&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for mitomycin C or nitrosoureas),&#xD;
             immunotherapy, biologic therapy, or other experimental drugs&#xD;
&#xD;
          -  At least 4 weeks since prior and no concurrent anti-androgens (e.g., flutamide,&#xD;
             estrogens, ketoconazole, PC-SPES, finasteride, or megestrol acetate)&#xD;
&#xD;
          -  At least 2 weeks since prior and no concurrent exogenous corticosteroids&#xD;
&#xD;
               -  Patients clinically proven to require maintenance steroids allowed provided there&#xD;
                  has been no change in their dose within the past 6 weeks&#xD;
&#xD;
          -  No antibiotic therapy within the past 72 hours&#xD;
&#xD;
          -  No prior organ transplantation&#xD;
&#xD;
          -  No prior salvage prostatectomy or brachytherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary&#xD;
             therapy considered investigational&#xD;
&#xD;
          -  No concurrent prophylactic use of colony-stimulating factors&#xD;
&#xD;
          -  No concurrent enrollment in any other study involving a pharmacologic agent (drugs,&#xD;
             biologics, immunotherapy approaches, gene therapy) whether for symptom control or&#xD;
             therapeutic intent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian J. Davis, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 7, 2008</study_first_submitted>
  <study_first_submitted_qc>November 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2008</study_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage II prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

